Summary
Late-stage chronic kidney disease (CKD), encompassing stage 4 and 5 CKD, is a disease that manifests in a host of co-morbidities. Of these, bone and mineral metabolism disorders are some of the most commonly treated and have significant impact on morbidity and mortality of patients. This report focuses on the current treatment landscape, unmet needs, pipeline and remaining opportunity in the late-stage CKD market with a focus on the treatment of hyperphosphatemia and secondary hyperparathyroidism (SHPT). GlobalData expects the late-stage CKD market to undergo significant flux over the next five years in the US and 5EU. This changeable landscape is a consequence of a number of contributory factors, including the patent expiries of market leading hyperphosphatemia brands, and the expected launch of three new entrants to the market. GlobalData expects US and European healthcare reimbursement reforms to have a drastic impact on the dialysis-dependent CKD market.

Key Findings
- The late-stage CKD therapeutics market (hyperphosphatemia and SHPT), in the 6MM is forecasted to decline from $1.88bn in 2012 to $1.66bn in 2017, at a CAGR of -2.5%.
- With the expected launch of three novel pipeline agents, the dialysis CKD market segment is due to become increasingly competitive over the forecast period as these agents enter a heavily generalized market.
- Interviewed experts report pipeline agents to have clinical advantages and expect them to partially address some key unmet needs. Remaining opportunities will be seized by future players who invest in considerable innovations through agents with novel mechanism of actions.

Scope
- Overview of late-stage CKD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Topline late-stage CKD therapeutics market revenue from 2012-2017. Annual cost of therapy, and major marketed and pipeline drug sales in this forecast period are included.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the late-stage CKD therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline drugs. An interactive clinical and commercial analyzer tool is available.

Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global late-stage CKD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global late-stage CKD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

To order this report:
Email: [email protected]
US: +1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE: Researchonglobalmarkets.com

RELATED LINK:
http://www.researchonglobalmarkets.com/opportunityanalyzer-late-stage-chronic-kidney-disease-ckd-opportunity-analysis-and-forecasts-to-2017.html